相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
S. Hipp et al.
LEUKEMIA (2017)
A ROR1 HER3 IncRNA signalling axis modulates the Hippo YAP pathway to regulate bone metastasis
Chunlai Li et al.
NATURE CELL BIOLOGY (2017)
Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer
C. E. Henry et al.
TRANSLATIONAL ONCOLOGY (2017)
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Ji Li et al.
CANCER CELL (2017)
miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer
Hong Tan et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
ROR1 Contributes to Melanoma Cell Growth and Migration by Regulating N-Cadherin Expression via the PI3K/Akt Pathway
Natalia Brenda Fernandez et al.
MOLECULAR CARCINOGENESIS (2016)
Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease
Jenny Potratz et al.
MOLECULAR ONCOLOGY (2016)
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
A. Viardot et al.
BLOOD (2016)
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
Bing Cui et al.
BLOOD (2016)
Chimeric antigen receptor T cell therapy: 25 years in the making
Saar Gill et al.
BLOOD REVIEWS (2016)
Targeting ROR1 inhibits the self-renewal and invasive ability of glioblastoma stem cells
Eun-Hwa Jung et al.
CELL BIOCHEMISTRY AND FUNCTION (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Expression of ROR1 has prognostic significance in triple negative breast cancer
Hui-Ping Chien et al.
VIRCHOWS ARCHIV (2016)
ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma
Yu-Zhu Zheng et al.
SCIENTIFIC REPORTS (2016)
Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma
Hyeyoon Chang et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2015)
Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1
Michael Y. Choi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo
Rajeswaran Mani et al.
EXPERIMENTAL HEMATOLOGY (2015)
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
Liping L. Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion
Claire Henry et al.
ONCOTARGET (2015)
Are BiTEs the missing link in cancer therapy?
Carter M. Suryadevara et al.
ONCOIMMUNOLOGY (2015)
Solitomab, an Epithelial Cell Adhesion Molecule/CD3 Bispecific Antibody (BiTE), Is Highly Active Against Primary Chemotherapy-Resistant Ovarian Cancer Cell Lines In Vitro and Fresh Tumor Cells Ex Vivo
Diana P. English et al.
CANCER (2015)
Bispecific T-cell engagers for cancer immunotherapy
Amelia M. Huehls et al.
IMMUNOLOGY AND CELL BIOLOGY (2015)
Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma
Yanchun Liu et al.
PLOS ONE (2015)
Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells
Carolina Berger et al.
CANCER IMMUNOLOGY RESEARCH (2015)
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
Michael D. Oberst et al.
MABS (2014)
Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy
Suping Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
ROR1 expression correlated with poor clinical outcome in human ovarian cancer
Huilin Zhang et al.
SCIENTIFIC REPORTS (2014)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2
Michael P. O'Connell et al.
CANCER DISCOVERY (2013)
The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers
Suping Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia
Vincent T. Bicocca et al.
CANCER CELL (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth
Suping Zhang et al.
PLOS ONE (2012)
Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies
Hema Dave et al.
PLOS ONE (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
ROR1 expression is not a unique marker of CLL
Gabor Barna et al.
HEMATOLOGICAL ONCOLOGY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
Sivasubramanian Baskar et al.
CLINICAL CANCER RESEARCH (2008)
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
Amir H. DaneshManesh et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis
Xavier Brochet et al.
NUCLEIC ACIDS RESEARCH (2008)
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal,antigen and receptor for Wnt5a
Tetsuya Fukuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
分享论文
